Fig. 3
Broad-spectrum neutralizing antibodies elicited by rVSV-SFTSV/AH12-GP and rVSV-eGFP-HRTV-GP in immunocompetent and immunocompromised mouse models. a–c Groups of six or five C57/BL6 mice, 6–8 weeks old, were i.p. immunized with 2 × 104 PFU of rVSV-SFTSV/AH12-GP a or rVSV-eGFP-HRTV-GP b. On day 30 post immunization, mouse sera were quantified for neutralization of rVSV-eGFP-SFTSV/AH12-GP (AH12), rVSV-eGFP-SFTSV/YG1-GP (YG1), rVSV-eGFP-HRTV-GP (HRTV), and control rVSV-eGFP-EBOV-GP (EBOV) via an FRNT assay. Each point represents one animal. c Sera from mice a, b immunized with rVSV-G (VSV), rVSV-SFTSV/AH12-GP (AH12), or rVSV-eGFP-HRTV-GP (HRTV) were also quantified for neutralization of SFTSV Wuhan (WH) strain via an FRNT assay. Each point represents one animal. Data are representative of three independent experiments (error bars represent SD). Significance was calculated using a multiple t test (****, P-value < 0.0001). d, e Six-to-eight-week-old IFNAR−/− C57/BL6 mice were i.p. immunized with a single dose of 2 × 104 PFU rVSV-SFTSV/AH12-GP d or rVSV-eGFP-HRTV-GP e. On day 30 post immunization, mouse sera were quantified for the neutralizing effect as above using rVSV-eGFP-HTNV-GP (HTNV) as control. Above data are representatives of three independent experiments and error bars indicate the SD. Significance was calculated using a multiple t test—one per row between control group and experimental groups (****P-value < 0.0001)
